Physician profile
Ruth K Fredericks
NPI 1730138843
$942,535.95
in general payments reported to CMS, 2019-2025
76 companies · $221K in 2025
The $221K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198K · 2020: $94K · 2021: $71K · 2022: $61K · 2023: $120K · 2024: $177K · 2025: $221K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $417K · Travel and Lodging: $59K · Consulting Fee: $21K · Food and Beverage: $19K · Honoraria: $2,763 · Education: $28.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $416,628.50 |
| Travel and Lodging | $59,049.55 |
| Consulting Fee | $20,816.00 |
| Food and Beverage | $19,158.06 |
| Honoraria | $2,762.50 |
| Education | $28.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $236,484.54 | 2019-2025 | Ultomiris, Soliris |
| Emd Serono, INC. | $191,315.79 | 2019-2025 | Mavenclad, Mavenclad, Evobrutinib |
| Biogen, INC. | $185,791.17 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Genentech USA, INC. | $53,220.66 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Lilly USA, LLC | $44,833.38 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Teva Pharmaceuticals USA, INC. | $43,927.38 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Tg Therapeutics, INC. | $42,937.31 | 2021-2025 | |
| Genzyme Corporation | $41,892.59 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $26,569.32 | 2019-2024 | Xarelto, Ponvory |
| Amgen INC. | $26,302.61 | 2019-2025 | Uplizna, Aimovig |
| Argenx US, INC. | $18,547.47 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Abbvie INC. | $8,778.66 | 2021-2025 | |
| Allergan, INC. | $4,576.16 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $3,232.51 | 2024-2025 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $1,914.32 | 2019-2025 | Hyqvia |
Show all 76 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,499.56 | 2019 | |
| Pfizer INC. | $1,311.13 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,192.58 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $712.48 | 2019-2025 | Nuplazid |
| Sk Life Science, INC. | $711.63 | 2020-2025 | |
| Celgene Corporation | $468.57 | 2021-2025 | Zeposia |
| Ucb, INC. | $465.84 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Medtronic, INC. | $378.13 | 2021-2025 | Linq II, Solitaire X |
| Jazz Pharmaceuticals INC. | $365.36 | 2021-2025 | Epidiolex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $355.74 | 2025 | Jardiance |
| Lundbeck LLC | $333.64 | 2019-2025 | Vyepti, Rexulti |
| Medtronic USA, INC. | $276.59 | 2019-2020 | |
| Boston Scientific Corporation | $274.65 | 2024-2025 | Watchman Access System, Wavewriter Alpha Prime 16 |
| Acorda Therapeutics, INC | $243.10 | 2019-2023 | Inbrija |
| Microtransponder, INC. | $228.67 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $224.93 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $214.72 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $212.26 | 2023-2025 | Nuedexta, Rexulti |
| Eisai INC. | $197.05 | 2021-2024 | |
| Catalyst Pharmaceuticals, INC. | $160.88 | 2023-2025 | Firdapse |
| E.R. Squibb & Sons, L.L.C. | $156.29 | 2019-2024 | Eliquis |
| Neurocrine Biosciences, INC. | $127.48 | 2020-2025 | Ingrezza, Ongentys |
| Sanofi-Aventis U.S. LLC | $127.26 | 2020-2021 | |
| Livanova USA, INC. | $126.23 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Impel Pharmaceuticals INC. | $125.83 | 2023 | Trudhesa |
| Supernus Pharmaceuticals, INC. | $118.15 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $117.36 | 2022-2025 | Wainua, Andexxa |
| Mdd US Operations, LLC | $116.67 | 2019-2024 | Apokyn, Apokyn, Xadago |
| Chiesi USA, INC. | $113.23 | 2020-2021 | |
| Greenwich Biosciences, INC. | $95.79 | 2019 | |
| Csl Behring | $85.95 | 2019-2023 | Kcentra |
| Amylyx Pharmaceuticals, INC. | $81.78 | 2023-2024 | Relyvrio |
| Biohaven Pharmaceutical Holding Company Ltd. | $80.93 | 2022 | |
| Mallinckrodt Hospital Products INC. | $79.13 | 2021-2025 | Acthar |
| Alnylam Pharmaceuticals INC. | $68.75 | 2024-2025 | Amvuttra, Givlaari |
| Tanabe Pharma America, INC. | $65.97 | 2023 | |
| Axsome Therapeutics, INC. | $57.80 | 2023-2025 | Sunosi, Symbravo |
| Horizon Therapeutics Plc | $57.67 | 2022-2023 | Uplizna |
| Sunovion Pharmaceuticals INC. | $49.26 | 2021 | |
| Corium, LLC | $46.54 | 2022-2023 | Adlarity |
| Mallinckrodt Enterprises LLC | $43.68 | 2019 | |
| Novocure INC. | $36.73 | 2023 | Optune |
| Ge Healthcare | $33.79 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $31.94 | 2025 | Ponvory |
| Merz Pharmaceuticals, LLC | $30.24 | 2024 | Xeomin |
| Arbor Pharmaceuticals, INC. | $28.03 | 2019 | |
| Penumbra, INC. | $26.61 | 2024 | Penumbra System |
| Ipsen Biopharmaceuticals, INC | $25.01 | 2023 | Dysport |
| Neurelis, INC. | $23.89 | 2023 | Valtoco |
| Adamas Pharmaceuticals, INC. | $23.55 | 2019 | |
| Grifols USA, LLC | $21.62 | 2021 | |
| Xeris Pharmaceuticals, INC. | $20.40 | 2024 | Keveyis |
| Ceribell, INC. | $17.83 | 2025 | Pocket Eeg Device |
| Phathom Pharmaceuticals, INC. | $17.81 | 2024 | Voquezna |
| Janssen Biotech, INC. | $17.09 | 2025 | |
| Kyowa Kirin, INC. | $16.84 | 2023 | Nourianz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.05 | 2025 | Caplyta |
| Amneal Pharmaceuticals LLC | $15.07 | 2024 | Ongentys |
| Idorsia Pharmaceuticals US INC | $14.54 | 2023 | Quviviq |
| Kedrion Biopharma, INC. | $14.32 | 2024 | Koate, Kedrab, Gammaked |
| Assertio Therapeutics, INC. | $11.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruth Fredericks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.